Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence

Katarzyna Korzeniowska, Jerzy Jankowski, Artur Cieślewicz, Anna Jabłecka Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poznan 61-848, PolandCorrespondence: Artur CieślewiczDepartment of Clinical Pharmacology, Poznan University of Medical Sciences, Długa 1/2 Str., Poznan...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Korzeniowska K, Jankowski J, Cieślewicz A, Jabłecka A
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2019
Sujets:	chemotherapy cardiotoxicity heart failure prevention Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/f80b7307cee940139e2c39ff4c6ac18d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:f80b7307cee940139e2c39ff4c6ac18d
record_format	dspace
spelling	oai:doaj.org-article:f80b7307cee940139e2c39ff4c6ac18d2021-12-02T10:51:31ZIs it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence1178-203Xhttps://doaj.org/article/f80b7307cee940139e2c39ff4c6ac18d2019-09-01T00:00:00Zhttps://www.dovepress.com/is-it-possible-to-prevent-chemotherapy-induced-heart-failure-with-card-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XKatarzyna Korzeniowska, Jerzy Jankowski, Artur Cieślewicz, Anna Jabłecka Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poznan 61-848, PolandCorrespondence: Artur CieślewiczDepartment of Clinical Pharmacology, Poznan University of Medical Sciences, Długa 1/2 Str., Poznan 61-848, PolandTel +48 61 854 9216Fax +48 61 853 3161Email artcies@ump.edu.plAbstract: Cardiovascular diseases and cancer are the most common death causes in the USA and Europe. Moreover, many patients suffer from both of these conditions – a situation which may result from cardiotoxicity of anticancer treatment. In order to reduce the severity of this adverse effect, various methods have been proposed, including the usage of new drug forms and less toxic analogs, omitting the combinations of potentially cardiotoxic drugs and introducing potential cardioprotective agents to the therapy. However, prevention of cardiotoxicity still seems to be insufficient. The article reviews the results of current studies on the use of cardiovascular drugs in the prevention of cardiotoxicity. Based on this knowledge, the most promising cardioprotective drugs seem to be carvedilol, nebivolol, enalapril, and candesartan, as they prevent heart remodeling and correct elevated resting heart rate, which directly affects mortality. Alternatively, in case of adverse reactions, statins might be considered.Keywords: chemotherapy, cardiotoxicity, heart failure, preventionKorzeniowska KJankowski JCieślewicz AJabłecka ADove Medical Pressarticlechemotherapycardiotoxicityheart failurepreventionTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 15, Pp 1095-1110 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemotherapy cardiotoxicity heart failure prevention Therapeutics. Pharmacology RM1-950
spellingShingle	chemotherapy cardiotoxicity heart failure prevention Therapeutics. Pharmacology RM1-950 Korzeniowska K Jankowski J Cieślewicz A Jabłecka A Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
description	Katarzyna Korzeniowska, Jerzy Jankowski, Artur Cieślewicz, Anna Jabłecka Department of Clinical Pharmacology, Poznan University of Medical Sciences, Poznan 61-848, PolandCorrespondence: Artur CieślewiczDepartment of Clinical Pharmacology, Poznan University of Medical Sciences, Długa 1/2 Str., Poznan 61-848, PolandTel +48 61 854 9216Fax +48 61 853 3161Email artcies@ump.edu.plAbstract: Cardiovascular diseases and cancer are the most common death causes in the USA and Europe. Moreover, many patients suffer from both of these conditions – a situation which may result from cardiotoxicity of anticancer treatment. In order to reduce the severity of this adverse effect, various methods have been proposed, including the usage of new drug forms and less toxic analogs, omitting the combinations of potentially cardiotoxic drugs and introducing potential cardioprotective agents to the therapy. However, prevention of cardiotoxicity still seems to be insufficient. The article reviews the results of current studies on the use of cardiovascular drugs in the prevention of cardiotoxicity. Based on this knowledge, the most promising cardioprotective drugs seem to be carvedilol, nebivolol, enalapril, and candesartan, as they prevent heart remodeling and correct elevated resting heart rate, which directly affects mortality. Alternatively, in case of adverse reactions, statins might be considered.Keywords: chemotherapy, cardiotoxicity, heart failure, prevention
format	article
author	Korzeniowska K Jankowski J Cieślewicz A Jabłecka A
author_facet	Korzeniowska K Jankowski J Cieślewicz A Jabłecka A
author_sort	Korzeniowska K
title	Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
title_short	Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
title_full	Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
title_fullStr	Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
title_full_unstemmed	Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
title_sort	is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/f80b7307cee940139e2c39ff4c6ac18d
work_keys_str_mv	AT korzeniowskak isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence AT jankowskij isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence AT cieslewicza isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence AT jabłeckaa isitpossibletopreventchemotherapyinducedheartfailurewithcardiovasculardrugsthereviewofthecurrentclinicalevidence
_version_	1718396565489451008

Is it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidence

Documents similaires